Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $3.0 million.

  • Editas Medicine's Other Non-Current Assets fell 4338.19% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 4338.19%. This contributed to the annual value of $5.2 million for FY2024, which is 3918.26% down from last year.
  • Editas Medicine's Other Non-Current Assets amounted to $3.0 million in Q3 2025, which was down 4338.19% from $4.2 million recorded in Q2 2025.
  • Editas Medicine's 5-year Other Non-Current Assets high stood at $9.5 million for Q1 2024, and its period low was $3.0 million during Q3 2025.
  • Moreover, its 5-year median value for Other Non-Current Assets was $6.8 million (2023), whereas its average is $6.3 million.
  • As far as peak fluctuations go, Editas Medicine's Other Non-Current Assets soared by 17971.56% in 2021, and later plummeted by 5575.0% in 2025.
  • Editas Medicine's Other Non-Current Assets (Quarter) stood at $6.8 million in 2021, then dropped by 22.87% to $5.3 million in 2022, then skyrocketed by 63.49% to $8.6 million in 2023, then crashed by 39.18% to $5.2 million in 2024, then tumbled by 42.75% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $4.2 million for Q2 2025, and $4.2 million during Q1 2025.